|
Company* (Country; Symbol) |
Product | Description | Indication | Status (Date) |
| AUTOIMMUNE | ||||
| Rigel Pharmaceuticals Inc. (RIGL) | R348 | An orally available inhibitor of Janus kinase 3 | Rheumatoid arthritis | Started enrolling patients in a Phase I trial (1/9) |
| Tolerx Inc.* | TRX1 | A humanized anti-CD4 monoclonal antibody | Refractory cutaneous lupus erythematosus | Completed a Phase Ib study (1/15) |
| CANCER | ||||
| AmpliMed* | Amplimexon | Imexon for injection | Metastatic melanoma | Positive Phase I/II survival results (1/3) |
| AVEO Pharmaceuticals Inc.* | AV-951 | Triple VEGF receptor inhibitor | Metastatic renal cell carcinoma | Started a Phase Ib trial of AV-951 in combination with the mTOR inhibitor temsirolimus (1/31) |
| Coronado Biosciences Inc.* | CNDO101 | 5-imino-13 deoxy-doxorubicin | Cancer | Dosed the first patient (1/7) |
| Exelixis Inc. (EXEL) | XL184 | A small molecule that inhibits the mesenchymal epithelial transition and vascular endothelial growth factor receptor tyrosine kinases | Non-small-cell lung cancer | Started a Phase I/II trial (1/7) |
| MethylGene Inc. (Canada; TSX:MYG) and Pharmion Corp. (PHRM) | MGCD0103 | An isotype-selective histone deacetylase inhibitor | Tumors | Phase I/II data showed it could be safely administered in combination with Eli Lilly's Gemzar (1/28) |
| Novacea Inc. (NOVC) | AQ4N | Banoxantrone | Acute lymphoblastic leukemia; glioblastoma multiforme | Is stopping a new trial in ALL, but will proceed with the Phase Ib/IIa trial in patients with glioblastoma multiforme (1/3) |
| Poniard Pharmaceuticals Inc. (PARD) | Picoplatin | Intravenous; a platinum-based chemotherapy agent | Metastatic colorectal cancer | Phase I data suggested picoplatin does not cause severe neuro-toxicity when used in combination with 5FU and leucovorin (1/28) |
| Protherics plc (UK; PTIL; LSE:PTI) and Advancell sl* (Spain) | Acadra | Acadesine | B-cell chronic lymphocytic leukemia | First patient was enrolled in a Phase I/II trial (1/11) |
|
Seattle Genetics Inc. (SGEN) and Genetech Inc. (NYSE:DNA) |
SGN-40 | A humanized monoclonal antibody targeting the CD40 antigen | Ralapsed follicular or marginal zone non-Hodgkin lymphoma | Started a Phase Ib trial (1/8) |
| SemaforePharmaceuticals Inc.* | SF1126 | P13 kinase inhibitor | Multiplemyeloma | Started a Phase I trial (1/7) |
| SGX Pharmaceuticals Inc. (SGXP) | SGX523 | An oral, small molecule inhibitor of the cMET tyrosine kinase | Advanced cancer | Started two Phase I trials (1/16) |
| Synta Pharmaceuticals Corp. (SNTA) | STA-9090 | Heat shock protein 90 inhibitor | Cancer | Started a second Phase I (1/18) |
| Tracon Pharmaceuticals Inc.* | TRC105 | A first-in-class human chimeric monoclonal antibody that binds to CD105 | Cancer | Dosed the first three patients (1/9) |
| Trion Pharma GmbH* (Germany) | Catumaxomab | A class of trifunctional antibodies | Advanced gastrointestinal cancers | Phase I results showed it was safe and well tolerated and led to substantial tumor cell destruction (1/28) |
| CARDIOVASCULAR | ||||
| Arena Pharmaceuticals Inc. (ARNA) | APD791 | A selective inverse agonist of the 5-HT2A serotonin receptor | Arterial thrombosis | Well tolerated up to 320 mg in a Phase I trial (1/9) |
| Arena Pharmaceuticals Inc. (ARNA) | Second-generation oral niacin receptor agonist | Atherosclerosis | Initiated a Phase I trial (1/25) | |
| Cytori Therapeutics (CYTX) | Adipose-derived stem and regenerative cells; uses Cytori's Celution System | Heart attack | Enrolled the first two patients in a clinical trial (1/30) | |
| ImaRx Therapeutics Inc. (IMRX) | MRX-801 | Microbubbles | Stroke | Closed the Phase I/II trial after an increase in intracranial hemorrhage events (1/4) |
| Metabasis Therapeutics Inc. (MBRX) | MB07811 | An oral, liver-targeted, beta-subtype-selective, thyroid hormone receptor agonist | Hyperlipidemia | Is well tolerated and reduces fasting low-density lipoprotein cholesterol levels and fasting triglyceride levels (1/4) |
| Myriad Genetics Inc. (MYGN) | MPC-0920 | An orally available direct thrombin inhibitor | For use as an anticoagulant | Phase I data demonstrated significant biological effect on clotting time and a desirable safety profile following oral administration (1/29) |
| Nuvelo Inc. (NUVO) | NU172 | A thrombin-inhibiting aptamer | To stimulate blood clot formation | Enrolled the first patient in a Phase I (1/30) |
| QuatRx Pharmaceuticals (QTRX) | QRX-431 | Lipid lowering drug sobetirome | To lower cholesterol | Phase I data showed that both single and multiple doses were well tolerated and lowered LDL cholesterol by as much as 22% with the single dose and 41% with multiple doses (1/29) |
| Resverlogix Corp. (Canada; TSX:RVX) | RVX-208 | A small molecule aimed at increasing the production of ApoA-1 and HDL | Cardiovascular disease | Phase I data showed no safety and tolerance problems in 40 healthy volunteers (1/14) |
| CENTRAL NERVOUS SYSTEM | ||||
| Allon Therapeutics Inc. (Canada; TSX:NPC) | AL-108 AL-208 | Intranasal administration; intravenous administration |
Cognitive impairment | Started dosing in a Phase I trial (1/10) |
| Alseres Pharmaceuticals Inc. (ALSE) | Cethrin | Contains a recombinant protein that inactivates the Rho enzyme to promote axon regeneration | Acute spinal cord injury | Completed enrollment of 48 patients in a Phase I/IIa trial (1/7) |
| CeNeRx BioPharma Inc.* | Tyrima | A reversible monoamine oxidase A inhibitor | Depression and anxiety | Completed its Phase I program, which showed the drug to be well tolerated (1/16) |
| Evotec AG (Germany; FSE:EVT) | EVT 302 | A reversible and highly selective inhibitor of MAO-B | Smoking cessation | Completed a Phase I study (1/7) |
| Javelin Pharmaceuticals Inc. (AMEX:JAV) | Dyloject | Injectable diclofenac sodium | Pain | It showed minimal effects upon platelet function at a clinically effective dose (1/8) |
| Neurogen Corp. (NRGN) | NGD-4715 | An MCH-1 receptor antagonist | Obesity | Phase I follow-up data showed no effect on lipids, but CYP3A4 induction was reduced substantially (1/8) |
| StemCells Inc. (STEM) | HuCNS-SC | Purified human neural stem cells | Batten disease | The death of a patient in a Phase I trial appears to be due to a viral infection and the natural progression of the disease and was not related to the drug (1/18) |
| Synosia Therapeutics* | SYN-111 | Rufinamide; a sodium channel blocker | General anxiety disorder | Completed the first trial and expects to start a Phase II later this year (1/22) |
| DIABETES | ||||
| Arena Pharmaceuticals Inc. (ARNA) | APD668 | Orally active glucose-dependent insulinotropic receptor agonist | Type II diabetes | Data showed it might improve glucose control but Ortho-McNeil has put the program on hold (1/8) |
| Genaera Corp. (GENR) | MSI-1436 | Trodusquemine | Type II diabetes | Began dosing subjects in a Phase I (1/17) |
| Lipoxen plc (UK; LSE:LPX) | SuliXen | A long-acting insulin candidate | Type I and Type II diabetes | Started a Phase I trial (1/28) |
| Oramed Pharmaceuticals Inc. (Israel; OTC BB:ORMP) | Oral insulin capsule | Diabetes | Started Phase Ib testing (1/22) | |
| INFECTION | ||||
| Antigenics Inc.(AGEN) | ACAM-FLU A | Vaccine | Influenza | Well tolerated; stimulates animmune response (1/3) |
| Nucleonics Inc.* | NUC B1000 | An expressed interfering RNA-based product consisting of a plasmid DNA construct designed to produce four short interfering RNA molecules | Chronic hepatitis B virus | Began treating patients in a Phase I trial (1/11) |
| Nventa Bio-pharmaceuticals Corp. (TSX:NVN) | HspE7 | A therapeutic vaccine candidate | Human papillomavirus | An assessment of the second co-hort of patients in a Phase I showed that safety data were normal (1/14) |
| Pharmasset Inc. (VRUS) | R7128 | A prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor | Hepatitis C virus | 85% of patients who received it in combination with Pegasys and Copegus achieved undetectable levels after four weeks (1/7) |
| Trius Therapeutics Inc.* | TR-701 | Antibacterial drug | Gram-positive bacterial infections | Started a Phase I trial (1/7) |
| MISCELLANEOUS | ||||
| HemaQuest Pharmaceuticals Inc.* | HQK-1001 | An oral drug | Sickle cell anemia and thalassemia | Started a Phase I trial (1/17) |
| Humanetics Corp.* | BIO 300 | A medical radiation countermeasure | Acute radiation syndrome | Completed a Phase I, which met all objectives and was well tolerated at all dose levels studied (1/11) |
| Morria Bio-pharmaceuticals plc* (UK) | MRX-4 | Nasally administered | Allergic rhinitis | Phase I data showed that the product resulted in no adverse effects observed in blood analysis (1/16) |
| N30 Pharma* | N30-201 | A nebulized formulation of s-nitrosoglutathione | Cystic fibrosis and asthma | Completed a Phase I study (1/28) |
| Nventa Bio-pharmaceuticals Corp. (TSX:NVN) | HspE7 | A therapeutic vaccine targeting human papilloma-virus-related diseases | Cervical dysplasia | Completed enrollment and initiated dosing of the third co-hort of patients in its Phase I trial (1/23) |
| Protox Therapeutics Inc. (Canada; CDNX:PRX) | PRX302 | Developed using the PORxin technology platform | Benign prostatic hyperplasia | The drug is safe and well tolerated (1/3) |
| TargeGen Inc.* | TG101348 | An oral, selective inhibitor of JAK2 | Myeloproliferative diseases | Started a Phase I/II trial (1/31) |
| Notes:* Privately held. Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.